A whistleblower’s allegations of illegal off-label marketing of hemostasis management drug, NovoSeven, has prompted Novo Nordisk, Inc. to pay $25 million. “Once approved by the FDA, a manufacturer may not market or promote a drug for any use not specified in its new drug application and approved by the FDA,” says DoJ.  “Such unapproved uses are also known as ‘off-label’ uses.”  The qui tam relators or “whistleblowers” who alerted the federal and state governments to the fraud, will be rewarded with almost $4,000,000.